Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 139

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1B
Chunk 139
---
 statements. 

 70

MiNK THERAPEUTICS, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS 

    For the Year EndedDecember 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    6,336,075

    $
    15,489,997

    General and administrative

    4,314,164

    7,431,108

    Change in fair value of related party note

    638,046

    —

    Operating loss

    (11,288,285
    )

    (22,921,105
    )

    Other income (expense), net:

    Interest income, net

    172,568

    463,256

    Other income (expense), net

    330,915

    (10
    )

    Net loss

    (10,784,802
    )

    (22,457,859
    )

    Per common share data:

    Basic and diluted net loss per common share
     
    $
    (2.86
    )
     
    $
    (6.54
    )

    Weighted average number of common shares outstanding

    3,773,326

    3,435,994

    Other comprehensive loss

    Foreign currency translation loss

    (200,629
    )

    (138,479
    )

    Comprehensive loss
     
    $
    (10,985,431
    )
     
    $
    (22,596,338
    )

See accompanying notes to consolidated financial statements.

 71

MiNK THERAPEUTICS, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT 

    Common Stock

    Treasury Stock

    Number ofshares

    ParValue

    AdditionalPaid-InCapital

    Number ofshares

    Amount

    OtherComprehensiveLoss

    AccumulatedDeficit

    Total

    Balance at December 31, 2022

    3,385,642

    $
    34

    $
    110,830,205

    —

    $
    —

    $
    (292,468
    )
     
    $
    (110,939,074
    )
     
    $
    (401,303